Agilent Technologies

This study was conducted to measure 12 elements in LiPF6 electrolyte and address the challenges of buildup of carbon on the torch of ICP-OES instruments.

Measurement of Al, Ca, Cd, Cu, Fe, K, Mg, Mn, Na, Ni, Pb, S, Si, and Zn in Li2CO3 using method of standard addition (MSA), in Lithium (Li)-ion batteries is demonstrated.

Fast, accurate determination of Fe, Al, As, Ba, Be, Cd, Co, Cr, Cu, K, Mg, Mn, Na, Ni, Pb, Sr, V, and Zn in graphite-based anode materials

Agilent 5110 VDV ICP-OES spectrometer used to establish rapid analysis method for determining impurities and major elements in lithium nickel cobalt manganate oxide

This compendium contains over 80 methods for the analysis of trace elements in a wide range of sample types across a wide range of industries.

These applications will help you find the right solution for your analytical needs. Agilent solutions build confidence and reliability in all your analytical measurements.

Partner with Agilent, benefit from industry-leading nucleic acid experience to advance lead oligo candidates from clinic to market with a goal of patient health and safety.

In living cells, the process of reversible hybridization is a critical requirement to the process of replication, transcription and translation.

The appetite for higher throughput analytical methods has increased in the past years alongside the acceleration of oligo production and use.

Synthetic DNA- and RNA-based oligonucleotides are among many successful biotherapeutic drugs to treat many different kinds of illnesses.

Oligonucleotides synthesized using phosphoramidite chemistry are analyzed and purified using ion-pair reversed-phase liquid chromatography and anion-exchange chromatography.

Oligonucleotides synthesized using phosphoramidite chemistry are analyzed and purified using ion-pair reversed-phase liquid chromatography and anion-exchange chromatography.

The purification of oligonucleotides (ONs) can be particularly challenging because of the high similarity of target and impurities.

The urgency caused by the SARS-CoV-2 pandemic of 2020 prompted policy makers and pharmaceutical firms alike to develop and deploy mRNA vaccines with unprecedented speed.